Vitamin D levels and bone mineral density: are LH levels involved in the pathogenesis of bone impairment in hypogonadal men?

Molecular Diagnosis and Therapy

Volumn 37, Issue 12, 2014, Pages 1225-1231

  Gioia, A ^a   Ceccoli, L ^a   Ronconi, V ^a   Turchi, F ^a   Marcheggiani, M ^a   Boscaro, M ^a   Giacchetti, G ^a   Balercia, G ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Bone; LH; Male hypogonadism; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ESTRADIOL; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG; UNDECANOATE TESTOSTERONE; VITAMIN D; BIOLOGICAL MARKER;

ADULT; ANDROGEN THERAPY; ARTICLE; BONE DENSITY; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; FEMUR NECK; FRAGILITY FRACTURE; HIP; HUMAN; HYPOGONADISM; LUMBAR SPINE; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL ACTIVITY; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; VITAMIN BLOOD LEVEL; AGED; BONE DISEASE; OSTEOLYSIS; BLOOD; PHYSIOLOGY;

ADULT; AGED; BIOMARKERS; BONE DENSITY; HUMANS; HYPOGONADISM; LUTEINIZING HORMONE; MALE; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 84940920261     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40618-014-0187-1     Document Type: Article

References (27)

1. Khosla S (2010) Update in male osteoporosis. J Clin Endocrinol Metab 95:3–10
2. Tuck SP, Francis RM (2009) Testosterone, bone and osteoporosis. Front Horm Res 37:123–132
3. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS (2012) Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:1802–1822
4. Amin S, Zhang Y, Felson DT, Sawin CT, Hannan MT, Wilson PW, Kiel DP (2006) Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham study. Am J Med 119:426–433
5. Bilezikian JP, Morishima A, Bell J, Grumbach MM (1998) Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599–603
6. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER (1997) Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337:91–95
7. Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, Wilson PW, Felson DT (2000) Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med 133:951–963
8. Behre HM, Kliesh S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386–2390
9. Khosla S, Amin S, Orwoll E (2008) Osteoporosis in men. Endocr Rev 29:441–464
10. Nicholls JJ, Brassill MJ, Williams GR, Bassett JH (2012) The skeletal consequences of thyrotoxicosis. J Endocrinol 213(3):209–221
11. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Swerdloff RS, Montori VM (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536–2559
12. Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ et al (2010) Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. J Clin Endocrinol Metab 95:1810–1818
13. Lee DM, Tajar A, Pye SR, Boonen S, Vanderschueren D, Bouillon R, O’Neill TW, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M, Wu FC (2012) Association of hypogonadism with vitamin D status: the European male ageing study. Eur J Endocrinol 166:77–85
14. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ et al (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363:123–135
15. Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672
16. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S (2008) International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone 43:1115–1121
17. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS (2004) Long-term testosterone gel (androgel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89:2085–2098
18. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremmer WJ, Tenover JL (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503–510
19. Benito M, Vasilic B, Wehrli FW, Bunker B, Wald M, Gomberg B, Wright AC, Zemel B, Cucchiara A, Snyder PJ (2005) Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res 20:1785–1791
20. Yaturu S, DjeDjos S, Alferos G, Deprisco C (2006) Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy. Prostate Cancer Prostatic Dis 9:35–38
21. Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS (2002) Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 56:779–786
22. Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhövel F (2003) Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 60:21–28
23. Trabado S, Maione L, Salenave S, Baron S, Galland F, Bry-Gauillard H, Guiochon-Mantel A, Chanson P, Pitteloud N, Sinisi AA, Brailly-Tabard S, Young J (2011) Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects of different modalities of hormonal treatment. Fertil Steril 95(7):2324–2329
24. Bellastella G, Pane E, Iorio S, De Bellis A, Sinisi AA (2013) Seasonal variations of plasma gonadotropin, prolactin, and testosterone levels in primary and secondary hypogonadism: evidence for an independent testicular role. J Endocrinol Invest 36:339–342
25. Foresta C, Selice R, De Toni L, Di Mambro A, Carraro U, Plebani M, Garolla A (2013) Altered bone status in unilateral testicular cancer survivors: role of CYP2R1 and its LH-dependency. J Endocrinol Invest 36:379–384
26. Foresta C, Strapazzon G, De Toni L, Perilli L, Di Mambro A, Muciaccia B, Sartori L, Serice R (2011) Bone mineral density and testicular failure: evidence for a role of vitamin D 25-hydroxylase in human testis. J Clin Endocrinol Metab 96:E646–E652
27. Wehr E, Pilz S, Boehm BO, Marz W, Obermayer PB (2010) Association of vitamin D status with serum androgen levels in men. Clin Endocrinol 73:243–248